NCT01841684

Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)

A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety and effect of anacetrapib on low-density lipoprotein-cholesterol (LDL-C) when added to ongoing lipid-lowering therapy. The primary hypothesis is that treatment with anacetrapib 100 mg for 12 weeks will lower LDL-C to a greater extent than treatment with placebo.

Conditions

• Hyperlipoproteinemia Type II
• Homozygous Familial Hypercholesterolemia

Interventions

Type	Name	Description
DRUG	Anacetrapib	100 mg tablet orally, once daily for 12 weeks
DRUG	Placebo	Placebo for anacetrapib orally, once daily for 12 weeks

Timeline

• Start date: 2013-06-01
• Primary completion: 2014-06-01
• Completion: 2014-06-01
• First posted: 2013-04-26
• Last updated: 2015-06-01